These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Scleroderma and related disorders: therapeutic aspects. Denton CP; Black CM Baillieres Best Pract Res Clin Rheumatol; 2000 Mar; 14(1):17-35. PubMed ID: 10882212 [TBL] [Abstract][Full Text] [Related]
5. Systemic sclerosis (scleroderma). Clinical management of its major complications. Legerton CW; Smith EA; Silver RM Rheum Dis Clin North Am; 1995 Feb; 21(1):203-16. PubMed ID: 7732169 [TBL] [Abstract][Full Text] [Related]
6. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment. Kumar N; Griffiths B; Allen J J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964 [No Abstract] [Full Text] [Related]
7. [Scleroderma and its visceral complications]. Huriez C Maroc Med; 1972 Jun; 52(558):331-44. PubMed ID: 4636029 [No Abstract] [Full Text] [Related]
8. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Herrick AL; Cutolo M Arthritis Rheum; 2010 Sep; 62(9):2595-604. PubMed ID: 20506306 [No Abstract] [Full Text] [Related]
9. [Systemic scleroderma in children]. Plantin P; Gavanou J; Le Fur JM; Guillet G Arch Fr Pediatr; 1988 Dec; 45(10):805-8. PubMed ID: 3266459 [TBL] [Abstract][Full Text] [Related]
10. Systemic sclerosis/scleroderma: a treatable multisystem disease. Hinchcliff M; Varga J Am Fam Physician; 2008 Oct; 78(8):961-8. PubMed ID: 18953973 [TBL] [Abstract][Full Text] [Related]
11. [Scleroderma and Raynaud's phenomenon: current pathogenetic interpretations and clinico-therapeutic trends]. Zelli GP; Cannata P Ann Ital Chir; 1981; 53(3):337-43. PubMed ID: 7337317 [No Abstract] [Full Text] [Related]
12. [Raynaud's syndrome and scleroderma. I. Scleroderma-like changes in Raynaud's syndrome and their differentiation from scleroderma]. JABLONSKA S; LUKASIAK B; BUBNOW B Pol Tyg Lek (Wars); 1957 Sep; 12(39):1481-6. PubMed ID: 13505250 [No Abstract] [Full Text] [Related]
13. Systemic sclerosis. Ng SC Singapore Med J; 1992 Apr; 33(2):189-92. PubMed ID: 1621127 [TBL] [Abstract][Full Text] [Related]
14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related]
15. [Systemic scleroderma]. Rommel A Sem Hop; 1984 Mar; 60(10):710-24. PubMed ID: 6322321 [TBL] [Abstract][Full Text] [Related]
16. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory. Czirják L; Matucci-Cerinic M Rheumatology (Oxford); 2011 Feb; 50(2):250-1. PubMed ID: 21115465 [No Abstract] [Full Text] [Related]
17. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Henness S; Wigley FM Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543 [TBL] [Abstract][Full Text] [Related]
18. [The use of Capoten in systemic scleroderma]. Guseva NG; Anikina NV; Shcherbakov AB Ter Arkh; 1992; 64(5):100-2. PubMed ID: 1455361 [TBL] [Abstract][Full Text] [Related]